NovartisNVS announced results from a phase III study, FUTURE 1, on Cosentyx for the treatment of psoriatic arthritis. The results were published in the New England Journal of Medicine . The multi center, randomized, placebo controlled phase III study
Novartis Announces Positive Data on Arthritis Drug Cosentyx
